September 16, 2016 10:03 AM EDTUpdated September 18, 11:43 PM
R&D

No­vo’s big re­veal: GLP-1 drug semaglu­tide cuts car­dio risks, but just may blind you

John Carroll

Editor & Founder

First, the good news for No­vo Nordisk’s di­a­betes drug semaglu­tide: The drug re­duced the num­ber of ma­jor car­dio events by 26% among high-risk pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times